Logo image of XBIO

XENETIC BIOSCIENCES INC (XBIO) Stock Fundamental Analysis

NASDAQ:XBIO - Nasdaq - US9840156023 - Common Stock - Currency: USD

3.07  -0.03 (-0.95%)

Fundamental Rating

3

XBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for XBIO as it has an excellent financial health rating, but there are worries on the profitability. XBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XBIO had negative earnings in the past year.
XBIO had a negative operating cash flow in the past year.
In the past 5 years XBIO always reported negative net income.
In the past 5 years XBIO always reported negative operating cash flow.
XBIO Yearly Net Income VS EBIT VS OCF VS FCFXBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

XBIO has a Return On Assets of -63.34%. This is in the lower half of the industry: XBIO underperforms 60.75% of its industry peers.
Looking at the Return On Equity, with a value of -71.60%, XBIO is in line with its industry, outperforming 53.76% of the companies in the same industry.
Industry RankSector Rank
ROA -63.34%
ROE -71.6%
ROIC N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
XBIO Yearly ROA, ROE, ROICXBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

XBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIO Yearly Profit, Operating, Gross MarginsXBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

XBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XBIO remains at a similar level compared to 1 year ago.
Compared to 5 years ago, XBIO has more shares outstanding
There is no outstanding debt for XBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XBIO Yearly Shares OutstandingXBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
XBIO Yearly Total Debt VS Total AssetsXBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

XBIO has an Altman-Z score of -44.37. This is a bad value and indicates that XBIO is not financially healthy and even has some risk of bankruptcy.
XBIO has a worse Altman-Z score (-44.37) than 92.29% of its industry peers.
There is no outstanding debt for XBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.37
ROIC/WACCN/A
WACC9.53%
XBIO Yearly LT Debt VS Equity VS FCFXBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

XBIO has a Current Ratio of 8.20. This indicates that XBIO is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.20, XBIO is doing good in the industry, outperforming 71.33% of the companies in the same industry.
A Quick Ratio of 8.20 indicates that XBIO has no problem at all paying its short term obligations.
XBIO's Quick ratio of 8.20 is fine compared to the rest of the industry. XBIO outperforms 71.51% of its industry peers.
Industry RankSector Rank
Current Ratio 8.2
Quick Ratio 8.2
XBIO Yearly Current Assets VS Current LiabilitesXBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.77% over the past year.
Looking at the last year, XBIO shows a small growth in Revenue. The Revenue has grown by 5.73% in the last year.
The Revenue has been growing by 162.66% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.36%
Revenue 1Y (TTM)5.73%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%16.14%

3.2 Future

XBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.30% yearly.
XBIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.35% yearly.
EPS Next Y-28.59%
EPS Next 2Y-33.05%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue Next Year27.27%
Revenue Next 2Y16.77%
Revenue Next 3Y4.35%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
XBIO Yearly Revenue VS EstimatesXBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
XBIO Yearly EPS VS EstimatesXBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XBIO. In the last year negative earnings were reported.
Also next year XBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIO Price Earnings VS Forward Price EarningsXBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIO Per share dataXBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as XBIO's earnings are expected to grow with 22.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.05%
EPS Next 3Y22.3%

More info and screens

0

5. Dividend

5.1 Amount

XBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENETIC BIOSCIENCES INC

NASDAQ:XBIO (6/4/2025, 6:33:58 PM)

3.07

-0.03 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners6.49%
Inst Owner Change20.22%
Ins Owners1.21%
Ins Owner Change0%
Market Cap4.73M
Analysts43.33
Price TargetN/A
Short Float %0.31%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-106.84%
Min EPS beat(2)-233.33%
Max EPS beat(2)19.66%
EPS beat(4)2
Avg EPS beat(4)-76.95%
Min EPS beat(4)-233.33%
Max EPS beat(4)19.66%
EPS beat(8)6
Avg EPS beat(8)-26.45%
EPS beat(12)8
Avg EPS beat(12)-13.49%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)81.51%
Min Revenue beat(2)-13.19%
Max Revenue beat(2)176.22%
Revenue beat(4)2
Avg Revenue beat(4)43.8%
Min Revenue beat(4)-19.71%
Max Revenue beat(4)176.22%
Revenue beat(8)4
Avg Revenue beat(8)27.38%
Revenue beat(12)8
Avg Revenue beat(12)36.67%
Revenue beat(16)12
Avg Revenue beat(16)49.83%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-390.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)55.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.83
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-4.55
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS1.68
BVpS3.33
TBVpS3.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.34%
ROE -71.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.2
Quick Ratio 8.2
Altman-Z -44.37
F-Score4
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.36%
EPS Next Y-28.59%
EPS Next 2Y-33.05%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue 1Y (TTM)5.73%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%16.14%
Revenue Next Year27.27%
Revenue Next 2Y16.77%
Revenue Next 3Y4.35%
Revenue Next 5YN/A
EBIT growth 1Y20.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.29%
EBIT Next 3Y-24.97%
EBIT Next 5YN/A
FCF growth 1Y36.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.32%
OCF growth 3YN/A
OCF growth 5YN/A